HEMATOLOGY & ONCOLOGY IN THE NORDICS

Malignant Haematology and Oncology are unique areas that require expert knowledge and insight

Not just by practicing physicians, but equally so for companies striving to be successful in this complex and rapidly transforming area.

Due to massive global and local investment in the field of malignancies,  diagnostics, disease understanding and true innovative treatments are materializing faster than for most other disease areas:

• Key opinion leaders defining treatment guidelines are faced with the positive problem of many new treatment options entering their field
• The market space has become highly competitive making it increasingly difficult to engage clinicians and key opinion leaders without an established network and presence.
• The Nordic countries’ public healthcare systems have been subject to considerable budget impacts that, in turn, is driving payers and clinics to counterbalance with new market access measures.

The introduction and maintenance of a successful product requires customized planning and tactics that need to be fully aligned with Danish, Finnish, Norwegian and Swedish market conditions and legislation.

Differences & Similarities… and opportunities

Treatment, Prescription and Reimbursement systems in the Nordic countries (Denmark, Finland, Norway, Sweden and Iceland) differ considerably from each other, making it a specialist task to ensure success.

The Nordic countries do have important similarities – many of which offer attractive opportunities for private-public co-ventures and data generation

• All Nordic citizens have a social security number that allows unique population scale epidemiological research – also in collaboration with the pharmaceutical industry
• The Nordic countries have an exceptional catalogue of registries and biobanks – particularly for malignancies
• Patient advocacy groups are well organised and active – even for many rare diseases
• Extensive and population scale screening programmes are also in place